TL13-112

CAS No. 2229037-19-6

TL13-112( —— )

Catalog No. M13566 CAS No. 2229037-19-6

TL13-112 is a novel Anaplastic Lymphoma Kinase (ALK)-PROTAC developed through conjugation of LDK378 and the cereblon ligand pomalidomide.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 284 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    TL13-112
  • Note
    Research use only, not for human use.
  • Brief Description
    TL13-112 is a novel Anaplastic Lymphoma Kinase (ALK)-PROTAC developed through conjugation of LDK378 and the cereblon ligand pomalidomide.
  • Description
    TL13-112 is a novel Anaplastic Lymphoma Kinase (ALK)-PROTAC developed through conjugation of LDK378 and the cereblon ligand pomalidomide; also promotes the degradation of additional kinases including PTK2 (FAK), Aurora A, FER, and RPS6KA1 (RSK1).
  • In Vitro
    TL13-112 binds to cereblon with an IC50 value of 2.4 uM.TL13-112 (0.01 μM-1 μM; 16 hours)?is selective for degradation of ALK with the DC50s of 10 nM and 40 nM in H3122 cell and Karpas 299, respectively. ALK degradation acts at 4 hours of treatment in H3122 cells and at 8 hours of treatment in Karpas 299 cells. The maximum degradation achieves at 16 hours in both cell lines. .TL13-112 (0.01 μM-1 μM; 16 hours) inhibits PTK2, ALK, FER, RPS6KA1 and Aurora A expression as a dose-dependent manner in H3122, Karpas 299, and Kelly cells. Western Blot Analysis Cell Line:H3122 and Karpas 299 cells Concentration:0.01 μM; 0.05 μM; 0.1 μM; 0.5 μM; 1 μM Incubation Time:16 hours Result:Inhibited ALK and Aurora A expression completely at 1 μM.Western Blot Analysis Cell Line:H3122 and Karpas 299 cells Concentration:0.01 μM; 0.05 μM; 0.1 μM; 0.5 μM; 1 μM Incubation Time:16 hours Result:Decreased PTK2, ALK, FER, RPS6KA1 and Aurora A expression.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    PROTACs
  • Target
    PROTAC
  • Recptor
    PROTAC
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2229037-19-6
  • Formula Weight
    1002.582
  • Molecular Formula
    C49H60ClN9O10S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (99.74 mM)
  • SMILES
    CC1=CC(=C(C=C1C2CCN(CC2)CCOCCOCCNC(=O)CNC3=CC=CC4=C3C(=O)N(C4=O)C5CCC(=O)NC5=O)OC(C)C)NC6=NC=C(C(=N6)NC7=CC=CC=C7S(=O)(=O)C(C)C)Cl
  • Chemical Name
    N-(2-(2-(2-(4-(4-((5-Chloro-4-((2-(isopropylsulfonyl)phenyl)-amino)pyrimidin-2-yl)amino)-5-isopropoxy-2-methylphenyl)-piperidin-1-yl)ethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Powell CE, et al. J Med Chem. 2018 May 10;61(9):4249-4255.
molnova catalog
related products
  • Lenalidomide-OH

    Lenalidomide-OH is an analog of cereblon (CRBN) ligand Lenalidomide for E3 ubiquitin ligase, and is used in the recruitment of CRBN protein.

  • BI-3663

    BI-3663 (BI 3663) is a cereblon-based degrader (PROTAC) of Focal adhesion tyrosine kinase (PTK2/FAK) with a median DC50 of 30 nM to >80% across a panel of eleven HCC cell lines.

  • THAL-SNS-032

    THAL-SNS-032 is a novel CDK9 degrader PROTAC consisting of a CDK-binding SNS-032 ligand linked to a thalidomide derivative that binds the E3 ubiquitin ligase Cereblon (CRBN).